Recombinant Human Olfactory receptor 2C3 (OR2C3)

What is the basic structure of the human OR2C3 protein?

OR2C3 is a G-protein-coupled receptor (GPCR) characterized by a 7-transmembrane domain structure common to the olfactory receptor family. The protein consists of 320 amino acids with a molecular weight of approximately 35-40 kDa. It shares the typical structural features of olfactory receptors, including extracellular, transmembrane, and intracellular domains that facilitate odorant binding and signal transduction. The receptor contains conserved motifs necessary for G-protein interaction and is encoded by a single coding-exon gene, which is typical for olfactory receptors. The amino acid sequence includes critical binding pocket residues that determine odor specificity and recognition properties, particularly within the transmembrane domains . The full amino acid sequence reveals a protein structure optimized for membrane insertion and odorant interaction, with specific regions contributing to ligand selectivity .

What signaling pathways does OR2C3 activate upon stimulation?

Upon odorant binding, OR2C3 undergoes conformational changes that activate G-protein-mediated signal transduction pathways. The primary pathway involves the activation of adenylyl cyclase through Gαolf (olfactory-specific G-protein alpha subunit), leading to increased intracellular cAMP levels. This elevation in cAMP opens cyclic nucleotide-gated channels, causing calcium influx and membrane depolarization. In non-olfactory tissues, particularly cancer cells, OR2C3 activation may trigger alternative signaling cascades, including phosphorylation of ERK1/2 and p38 MAPK, which can influence cellular processes such as proliferation, migration, and apoptosis . These signaling pathways can vary depending on the cellular context and may explain the diverse physiological roles of OR2C3 beyond olfaction, particularly in pathophysiological conditions like cancer development where OR2C3 has been implicated in melanoma progression .

What are the known synonyms and alternative designations for OR2C3?

The human olfactory receptor OR2C3 has several synonyms and alternative designations in scientific literature and databases. According to genomic and proteomic annotations, OR2C3 is also known as olfactory receptor, family 2, subfamily C, member 4 (OR2C4), olfactory receptor 2C5 (OR2C5P), and olfactory receptor OR1-30. Additional designations include OST742 and identifiers specific to various genomic databases. The variety of names reflects historical naming conventions as well as refinements in nomenclature as our understanding of the olfactory receptor family has evolved . It is important for researchers to recognize these alternative designations when conducting literature reviews or database searches to ensure comprehensive coverage of relevant research. The formal nomenclature for olfactory receptors follows specific guidelines established for each organism, making cross-species comparisons sometimes challenging without proper synonym mapping.

What are the most effective techniques for expressing recombinant OR2C3 protein?

Expression of functional recombinant OR2C3 presents significant challenges due to poor membrane trafficking and potential toxicity to expression hosts. The most effective approach utilizes mammalian expression systems, particularly the Hana3A cell line, which is specifically engineered for olfactory receptor expression. This method employs an N-terminal rhodopsin tag (first 20 amino acids of bovine rhodopsin) to enhance membrane trafficking and surface expression. Co-expression with receptor-transporting proteins (RTPs), particularly RTP1S, significantly improves trafficking efficiency of OR2C3 to the cell membrane . For protein production purposes, E. coli-based expression systems can generate recombinant OR2C3 with His-tags for purification, though these systems may not produce properly folded, functional receptors. Baculovirus-insect cell systems represent an alternative that balances yield with proper post-translational modifications. Successful expression typically requires optimization of codon usage, temperature, and induction conditions specific to OR2C3's amino acid sequence and structural characteristics .

How can researchers validate OR2C3 activation in cellular assays?

Validation of OR2C3 activation in cellular assays requires sensitive detection methods that capture the downstream signaling events following receptor stimulation. The most widely used approach employs a luciferase-based reporter system in Hana3A cells, where a cAMP-responsive element drives luciferase expression upon OR activation. This system allows quantitative measurement of receptor responses to potential ligands. Alternative validation methods include calcium imaging using fluorescent calcium indicators (e.g., Fura-2, Fluo-4) to detect intracellular calcium flux following receptor activation, or direct measurement of cAMP production using ELISA or FRET-based assays . For more detailed mechanistic studies, researchers should consider measuring the phosphorylation of downstream signaling proteins such as ERK1/2 and p38 MAPK using phospho-specific antibodies in immunoblotting assays. Cell-based assays have achieved impressive validation rates, with some studies reporting 70% success rates in confirming computationally predicted agonists and antagonists for olfactory receptors . These cellular experiments are crucial for validating proposed binding mechanisms between OR2C3 and potential ligands.

What approaches can be used to identify potential ligands for OR2C3?

Identifying ligands for orphan receptors like OR2C3 (deorphanization) employs multiple complementary approaches. High-throughput screening represents the traditional method, wherein libraries of odorants are tested against cells expressing OR2C3 using reporter assays that measure receptor activation. More recently, computational approaches have gained prominence, including:

• Virtual screening through molecular docking, which predicts binding affinities between OR2C3 and potential ligands based on structural models

• Protein Chemistry Metric (PCM) models that leverage machine learning to predict receptor-ligand interactions based on sequence similarity and physicochemical properties

• Structure-based design informed by homology models or predicted structures

These computational methods have demonstrated remarkable efficiency, with hit rates of approximately 58-70% when validated by cellular assays . The PCM model developed by Jérôme Golebiowski's team has successfully predicted novel odorant-OR pairs using just 20% of the residue sequence, focusing on the 60 residues surrounding the binding pocket. This approach has identified 64 novel odorant-OR pairs, demonstrating its effectiveness for deorphanization efforts . Integration of computational predictions with experimental validation provides the most robust approach for ligand identification.

What evidence supports OR2C3's role in cancer development or progression?

Emerging evidence indicates OR2C3's potential role in cancer, particularly in melanoma. Research by Ranzani et al. demonstrated OR2C3 expression patterns in melanoma that strongly suggest functional involvement in either the development or progression of this cancer type . This finding aligns with broader observations regarding ectopic expression of olfactory receptors in multiple cancer types. While the precise mechanisms remain under investigation, the pattern of OR2C3 expression in melanoma tissues compared to normal tissues suggests a non-random association with tumorigenesis. The receptor's potential involvement in cell proliferation, migration, or survival pathways makes it a compelling target for further investigation. Similar to other olfactory receptors that have been implicated in cancer (such as OR51E2 in prostate cancer and OR7C1 in colon cancer), OR2C3 may influence key cellular processes through activation of signaling cascades that affect cancer cell behavior . The specificity of OR2C3's expression in melanoma suggests it could serve as a biomarker or therapeutic target, similar to other olfactory receptors that have shown promise as cancer biomarkers.

How does OR2C3 expression in cancer tissues compare to normal tissues?

Comparative analysis of OR2C3 expression across multiple tissue types reveals significant differences between cancer and normal tissues, suggesting potential diagnostic or therapeutic relevance. While normal tissues generally show limited OR2C3 expression, certain cancers demonstrate notably elevated levels. In melanoma specifically, OR2C3 shows expression patterns that differ markedly from normal melanocytes, suggesting cancer-specific alterations in gene regulation . This differential expression pattern follows similar trends observed with other olfactory receptors in different cancer types. For instance, OR2B6 shows pronounced expression in over 80% of breast carcinoma tissues and 70% of breast carcinoma cell lines, while being absent in normal breast tissues . Expression values in cancer tissues can reach notably high levels for ectopically expressed olfactory receptors, with FPKM values ranging from 0.1 to 10.6 in some cases. The cancer-specific expression patterns of olfactory receptors like OR2C3 emphasize their potential utility as biomarkers and their possible functional roles in oncogenesis or tumor progression.

What methodologies are most effective for studying OR2C3 in cancer models?

Investigating OR2C3 in cancer contexts requires specialized approaches that combine molecular, cellular, and computational techniques. The most effective methodologies include:

• Transcriptomic profiling: RNA-Seq analysis provides comprehensive quantitation of OR2C3 expression across cancer and normal tissues. This approach has been successfully used to identify differential expression patterns, with data visualization through platforms like the Integrative Genomic Viewer .

• Functional studies: Knockdown and overexpression experiments in cancer cell lines help establish causality between OR2C3 expression and cancer phenotypes. These can be coupled with cellular assays measuring proliferation, migration, invasion, and apoptosis.

• Signaling pathway analysis: Phosphorylation studies identifying activated downstream effectors (ERK1/2, p38 MAPK) help elucidate the mechanisms by which OR2C3 influences cancer cell behavior .

• Ligand identification: For functional characterization, identifying endogenous ligands that activate OR2C3 in cancer contexts is crucial. This can be accomplished through computational prediction followed by experimental validation using cellular activation assays .

• In vivo models: Xenograft models using cell lines with modified OR2C3 expression provide insights into the receptor's influence on tumor growth and metastasis.

Integration of these methodologies provides the most comprehensive understanding of OR2C3's role in cancer development and progression, potentially revealing new therapeutic approaches or diagnostic markers.

How can researchers utilize current computational tools to model OR2C3 structure?

Modern computational approaches offer powerful methods for modeling OR2C3 structure despite the historical challenges in crystallizing GPCRs. The most effective current approach utilizes AI-based structure prediction tools like AlphaFold2, which can generate high-confidence structural models of OR2C3 based solely on amino acid sequence. These predicted structures provide crucial insights into binding pocket architecture and potential ligand interactions . For refinement and validation of these models, molecular dynamics simulations are essential, allowing researchers to assess structural stability and conformational dynamics in a simulated membrane environment. Cryo-electron microscopy (Cryo-EM) templates from structurally related GPCRs can further enhance model accuracy by providing experimental anchors for comparative modeling . Recent advancements in computational methods have dramatically improved the reliability of OR2C3 structural predictions, enabling more informed structure-based drug design and ligand discovery efforts. Researchers should apply multiple complementary computational approaches and validate structural predictions through experimental methods whenever possible to achieve the most accurate OR2C3 models.

What are the key considerations in molecular dynamics simulations of OR2C3?

Molecular dynamics simulations of OR2C3 require careful consideration of multiple factors to ensure physiologically relevant results. The critical considerations include:

• Membrane environment modeling: OR2C3 must be simulated within a lipid bilayer that mimics the composition of the native membrane environment. This typically involves POPC or mixed lipid bilayers that include cholesterol, which significantly affects GPCR dynamics.

• Ion binding sites: Simulations should account for the conserved sodium binding site near residues D2.50 and E3.39, which has been demonstrated to stabilize the inactive state of olfactory receptors. Research indicates that this sodium ion is essential for maintaining proper receptor conformation .

• Simulation duration: Due to the slow conformational changes typical of GPCRs, extended simulation times (typically microseconds) are necessary to observe relevant conformational dynamics of OR2C3.

• Force field selection: The choice of force field significantly impacts simulation accuracy, with CHARMM36 and AMBER force fields commonly used for membrane protein simulations.

• Water model and solvation: Proper solvation with explicit water molecules and physiological ion concentrations is essential for realistic electrostatic interactions.

These considerations ensure that molecular dynamics simulations of OR2C3 capture physiologically relevant dynamics and provide meaningful insights into receptor function, ligand binding, and activation mechanisms.

How can machine learning approaches enhance OR2C3 ligand discovery?

Machine learning methodologies have revolutionized OR2C3 ligand discovery by significantly accelerating the identification of potential agonists and antagonists while improving success rates. State-of-the-art approaches leverage multiple data types to train predictive models:

• Protein Chemistry Metric (PCM) models: These models combine OR sequence similarity with physicochemical properties of known ligands to predict novel interactions. Particularly effective is the model developed by Jérôme Golebiowski's team, which achieved a 58% hit rate and discovered 64 novel odorant-OR pairs by focusing on just 60 residues surrounding the binding pocket .

• Deep learning for structural prediction: Neural networks trained on protein structure databases can predict binding pocket conformations and ligand interactions with increasing accuracy, enabling virtual screening of compound libraries.

• Supervised learning algorithms: Models trained on known OR-ligand pairs can identify patterns in physicochemical properties that predict binding affinities, with some approaches achieving 70% success rates when validated through cellular assays .

• Feature extraction from molecular dynamics: Machine learning can identify key interaction patterns from simulation data, revealing essential binding characteristics.

The integration of these machine learning approaches with traditional molecular modeling and experimental validation creates a powerful workflow for OR2C3 deorphanization. This combined approach is particularly valuable given the challenges associated with experimental screening of the vast chemical space of potential odorants.

How can OR2C3 be utilized as a biomarker in cancer diagnostics?

OR2C3's potential as a cancer biomarker stems from its specific expression patterns in certain cancer types, particularly melanoma. To develop OR2C3 as an effective biomarker, researchers should consider several methodological approaches. RNA-based detection methods, including qRT-PCR and RNA-Seq, can quantify OR2C3 transcript levels in patient samples with high sensitivity. These approaches have already demonstrated success with other olfactory receptors, such as OR2B6 in breast cancer, where expression was detected in over 80% of breast carcinoma tissues but absent in normal breast tissue . Protein-based detection using immunohistochemistry or Western blotting with validated antibodies provides spatial information about OR2C3 expression within tumor tissues. For clinical application, threshold values must be established that differentiate between normal variation and cancer-associated expression, requiring large cohort studies with carefully matched control samples. Researchers should also investigate correlations between OR2C3 expression and clinicopathological features such as tumor stage, grade, and patient outcome to determine prognostic value. Combination with other biomarkers may enhance diagnostic accuracy, as single-marker approaches rarely achieve sufficient specificity and sensitivity for clinical implementation.

What are the challenges in developing compounds that target OR2C3?

Developing compounds that specifically target OR2C3 presents several significant challenges that researchers must address through methodical approaches. The high sequence similarity between different olfactory receptors (ORs) makes achieving specificity difficult, requiring careful structure-based design informed by binding pocket analysis. Traditional medicinal chemistry approaches combining computational prediction with systematic structural modifications can help identify moieties that enhance OR2C3 selectivity. Researchers must also address the challenge of receptor promiscuity, as ORs typically respond to multiple odorants with varying affinities, complicating the identification of highly specific ligands . The development of radio-labeled or fluorescent probes for OR2C3 would significantly advance research capabilities by enabling direct binding assays and receptor localization studies. To overcome limitations in functional assays, investigators should implement multiple complementary methods for measuring receptor activation, including cAMP assays, calcium imaging, and receptor internalization studies. Finally, compounds must be optimized for appropriate pharmacokinetic properties if intended for in vivo applications, with special consideration for delivery to target tissues, particularly if targeting OR2C3 in melanoma or other cancers .

How might OR2C3 functional studies contribute to understanding olfactory coding?

OR2C3 functional studies offer valuable insights into the broader principles of olfactory coding, with methodological approaches that connect molecular mechanisms to perception. Deorphanization of OR2C3 through identification of its ligand repertoire contributes to mapping the olfactory receptor-odorant interaction space, a fundamental aspect of understanding how the brain interprets chemical stimuli. Structure-function studies involving site-directed mutagenesis of key binding pocket residues help establish the molecular determinants of odorant recognition, providing empirical data to support computational models of olfactory receptor activation . The 7-transmembrane structure typical of ORs, including OR2C3, features conserved motifs across the receptor family that influence ligand specificity and signal transduction efficiency. By studying these structural elements in OR2C3, researchers can identify common activation mechanisms across the OR family. The integration of OR2C3 functional data with broader olfactory system studies bridges the gap between molecular interactions and perceptual outcomes, contributing to our understanding of how combinatorial receptor activation patterns encode odor identity, intensity, and hedonic value. These studies may also reveal insights into receptor evolution and adaptation, as OR2C3 belongs to the largest gene family in the genome, with significant diversity across species.

What novel protein expression systems might improve OR2C3 production?

Innovative protein expression systems offer promising approaches to overcome the traditional challenges associated with OR2C3 production. Cell-free expression systems provide a rapidly evolving alternative that bypasses cellular toxicity issues often encountered with membrane proteins. These systems can be supplemented with nanodiscs, micelles, or liposomes to create membrane-like environments for proper OR2C3 folding. Engineered eukaryotic expression hosts, including modified yeast strains (Pichia pastoris, Saccharomyces cerevisiae) with enhanced membrane protein processing capabilities, represent another innovative approach. These systems combine high yield with proper post-translational modifications essential for OR2C3 functionality . Mammalian cell lines specifically engineered for olfactory receptor expression beyond the traditional Hana3A system could further improve expression efficiency. Technologies incorporating self-cleaving 2A peptides to co-express OR2C3 with chaperones and trafficking proteins in precise stoichiometric ratios may enhance membrane integration. Finally, transient expression systems utilizing viral vectors optimized for membrane protein delivery offer advantages for rapid production of OR2C3 for structural and functional studies. These technological innovations collectively address the fundamental challenges of producing functional olfactory receptors for research applications.

How can single-cell analysis techniques advance OR2C3 research?

Single-cell analysis techniques offer unprecedented resolution for investigating OR2C3 expression, localization, and function at the individual cell level, revealing heterogeneity masked in bulk tissue analyses. Single-cell RNA sequencing (scRNA-seq) enables precise quantification of OR2C3 transcript levels across cell populations, particularly valuable for studying rare cell types expressing this receptor in non-olfactory tissues or cancer samples. This approach has revolutionized our understanding of cell-specific expression patterns . Mass cytometry (CyTOF) with OR2C3-specific antibodies allows simultaneous analysis of multiple proteins alongside OR2C3, providing insights into associated signaling pathways and receptor co-expression patterns. In situ hybridization techniques like RNAscope offer spatial information about OR2C3 expression within tissue contexts while maintaining single-cell resolution. For functional studies, microfluidic platforms that isolate individual cells can measure real-time responses to OR2C3 ligands through calcium imaging or electrophysiological recordings. Combined with genetic manipulation techniques like CRISPR-Cas9, these approaches enable precise investigation of OR2C3's functional role in specific cellular contexts, advancing our understanding of this receptor beyond what conventional bulk analyses can achieve.

What are the emerging applications of organoid technology in studying OR2C3?

Organoid technology offers novel platforms for investigating OR2C3 in physiologically relevant three-dimensional contexts that recapitulate tissue architecture and cellular diversity. Olfactory epithelium organoids derived from stem cells provide exceptional models for studying OR2C3 in its native context, allowing investigation of receptor expression, trafficking, and function during cellular differentiation and maturation. These systems enable long-term studies of receptor dynamics not possible in traditional 2D cultures . For cancer research applications, patient-derived tumor organoids that maintain OR2C3 expression offer powerful models for investigating the receptor's role in tumor development and for screening potential therapeutic compounds targeting OR2C3-dependent pathways . Brain organoids incorporating olfactory bulb regions present opportunities to study OR2C3's role in neural circuit formation and function, particularly the connections between peripheral sensory neurons and central processing systems. The combination of organoid technology with gene editing approaches such as CRISPR-Cas9 enables precise manipulation of OR2C3 expression or sequence to evaluate functional consequences in complex cellular environments. These emerging applications of organoid technology expand the methodological toolkit available to researchers investigating OR2C3, bridging the gap between simplified cell culture systems and complex in vivo models.